Figure 3From: Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPDDifferences and 95% CIs between roflumilast and placebo for increase in pre-bronchodilator FEV 1 (L) by patient subgroup. Error bars represent 95% CIs.Back to article page